At the news
? NEUTRALIMPACT 4/10 8-K filed Jun 5, 2026 at 16:29 ET
NovoCure held its 2026 annual general meeting on June 3, 2026, re-electing all 11 director nominees and approving the Amended and Restated 2024 Omnibus Incentive Plan by a razor-thin margin (50.3% for vs. 49.7% against). The omnibus plan approval was highly contested, with nearly as many votes against as for, signaling significant shareholder dissent on equity compensation. The filing is routine in nature but the close vote on the incentive plan is a notable governance signal.
- All 11 director nominees were elected with strong support (lowest 'for' vote was 79,455,754 for Kinyip Gabriel Leung).
- The Amended and Restated 2024 Omnibus Incentive Plan was approved with 41,680,622 votes for and 41,161,139 against, a margin of only 519,483 shares (50.3% for).
- Shareholder turnout was 81.01% (93,826,730 shares voted).
- The omnibus plan authorizes up to 18,000,000 ordinary shares for future equity awards, less shares granted under the prior plan after April 2, 2024.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access